Avenzo Therapeutics的动态

Non-muscle invasive bladder cancer (NMIBC) is a disease with a significant patient burden, high clinical needs and massive economic impact on our healthcare system. We are excited to be presenting three posters at #GU25 to highlight the status of our ongoing clinical trial with the bladder cancer community and underscore our commitment to providing treatment innovation for underserved conditions, with the potential to mainstream genetic medicines. #GU25?

Joint EANM?SNMMI guideline on the role of 2?[18F]FDG PET/CT in no special type breast cancer (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA) - Summary of the 2-[18F]FDG PET/CT recommendations according to the clinical scenario in NST breast cancer

Save the Date: 2024 Updates in Oncology Conference on August 2 Join the University of Cincinnati Cancer Center for an educational conference on the latest advancements in cancer care for solid tumors. Our team of experts, alongside external keynote speaker Priyanka Sharma, MD, will share important insights and highlights from the most recent ASCO Conference. Stay informed with the latest developments in cancer research and treatment. #CancerResearch #ASCO2024

??We share the #Review "Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges" ??by Lorenzo Guidi et al. Access the full paper here?? https://lnkd.in/dByNUp2W Keywords: HER2-positive breast cancer; antibody-drug conjugates; trastuzumab emtansine

In paper 9 of the 2023 SAHR, Peresu et al. explore the factors influencing uptake of breast cancer screening. See an overview of their paper here... https://lnkd.in/dwgXzFJG

To wrap up the prostate cancer series at #ESMO24, Dr. Eleni Efstathiou and colleagues share insights on everything from ARANOTE to Contact-02 in the final roundtable coverage. https://lnkd.in/eHx237r5

FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer https://lnkd.in/eB6_xFfS ?? @myESMO #MedicalOncology #CancerNews #Oncology #Cancer

Theragnostic approaches in cervical cancer treatment. A path for improving treatment efficacy and personalized strategies

Very interesting comment and perspective on the I-SPY platform (https://lnkd.in/eaJSUmav). I-SPY 'clinical trials are creating a roadmap for a new clinical research vision that cuts inefficiencies, puts patients first, and defines a viable pathway for precision-based drug development. The question now is whether others will replicate the approach outside of breast cancer.' Interesting approach with a variety of applications. See Biocentury article: https://lnkd.in/em4SipbT

Last month, we announced exciting results from our phase 3 CAN-2409 trial in localized prostate cancer, showing significant improvements in disease-free survival and pathological complete response rates. After decades without major advances in this space, CAN-2409 combined with valacyclovir and radiation therapy shows real promise in transforming the standard of care for intermediate/high-risk prostate cancer patients. Read more in OncLive: https://lnkd.in/ep5Q5sQF